Valentín Ortiz-Maldonado – VJRegenMed

ARI-0001 CART19 cells in R/R B-ALL with isolated extramedullary disease

admin_vjr_user — Fri, 26 Feb 2021 14:08:22 +0000

Valentín Ortiz-Maldonado, MD, Hospital Clínic de Barcelona, Barcelona, Spain, discusses the safety and efficacy outcomes of ARI-0001 CART19 cell therapy in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) with isolated extramedullary disease. Results show a good safety profile, the incidence of cytokine-release syndrome (CRS) was 40%, and no cases of immune effector cell-associated neurotoxicity syndrome (ICANS) were observed. Additionally, ARI-0001 therapy was able to achieve long-term remissions in this population of patients. This interview took place during the 3rd European CAR T-cell Meeting.

ARI-0001 in CD19+ malignancies: next steps

Marta Palhas — Fri, 26 Feb 2021 14:08:21 +0000

Valentín Ortiz-Maldonado, MD, Hospital Clínic de Barcelona, Barcelona, Spain, shares that the CD19 CAR-T cell product, ARI-0001, is currently under review for approval by the Spanish Drug Agency (AEMPS) under the Hospital Exemption Rule. In addition to this, a Phase II multicenter clinical trial is starting in adult acute lymphoblastic leukemia (ALL) with ARI-0001 cell therapy but with a higher dose to improve the duration of response. This interview took place during the 3rd European CAR T-cell Meeting.

CART19-BE-01: ARI-0001 in CD19+ malignancies

admin_vjr_user — Tue, 03 Nov 2020 17:40:00 +0000

Valentín Ortiz-Maldonado, MD, of the Hospital Clinic, Barcelona, Spain, discusses the initial results of the CART19-BE-01 (NCT03144583), a Phase I multicenter study evaluating ARI-0001, a CD19 targeting chimeric antigen receptor T-cell, in patients with CD19+ relapsed/refractory hematological malignancies. The primary and secondary endpoints of safety and efficacy were met, with an overall survival of 68.6% at one year. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

Challenges associated with CAR T-cell production

admin_vjr_user — Thu, 08 Oct 2020 14:08:12 +0000

Valentín Ortiz-Maldonado, MD, Hospital Clinic, Barcelona, Spain, discusses challenges associated with CAR T-cell production. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

Sinusoidal obstruction syndrome in patients with R/R B-cell ALL

admin_vjr_user — Thu, 08 Oct 2020 14:08:11 +0000

Valentín Ortiz-Maldonado, MD, Hospital Clinic, Barcelona, Spain, discusses sinusoidal obstruction syndrome in patients with relapsed-refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) treated with ARI-0001 CAR T-cells. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).